Bayer licenses Nektar technology in $175M deal

Bayer Healthcare has nabbed a deal with Nektar Therapeutics to develop and commercialize Nektar's remedy for gram-negative pneumonia, known as inhaled amikacin. Bayer will pay $50 million up front, plus an additional $125 million in milestone payments if they successfully bring the compound to market. Profits on eventual U.S. sales will be shared 50-50.

- check out the release

Related Articles:
Nektar settles university patent fight. Report
Nektar gains fast track for lung infection drug. Report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.